BofA analyst Jeffrey Spector lowered the firm’s price target on Sabra Health Care (SBRA) to $20 from $21 and keeps a Buy rating on the shares. Based on recent property tours, quarter-to-date updates and the proximity to when 2025 guidance was initiated, the firm expects “mainly beats and meets for 1Q results” and expects a good earnings season for REITs, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care price target raised to $18 from $17 at Truist
- Sabra Healthcare Reit Projects Positive 2025 Amid Growth
- Sabra Healthcare REIT Reports Strong Q4 2024 Results
- Sabra Healthcare REIT: Hold Rating Amid Stable Financials and Cautious Growth Strategy
- Sabra Health Care reports Q4 AFFO 36c, consensus 36c